



06-26-07.

PPS
\$

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0654-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/809,689
	Filing Date	March 25, 2004
	First Named Inventor	Mark Larche
	Art Unit	1644
	Examiner Name	N. M. Rooney
Total Number of Pages in This Submission	Attorney Docket Number	2004(217246)

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): IDS (Citation) by Applicant (21 References) (2 pages) Certificate of Express Mailing (1 pg) Charge \$180.00 to Deposit Account 04-1105 Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Matthew M. Beaudet		
Date	April 24, 2007	Reg. No.	50,649



Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2007		Complete if Known	
		Application Number	10/809,689
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	March 25, 2004
TOTAL AMOUNT OF PAYMENT (\$) 180.00		First Named Inventor	Mark Larche
		Examiner Name	N. M. Rooney
		Art Unit	1644
		Attorney Docket No.	2004(217246)

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: <u>04-1105</u> Deposit Account Name: <u>Edwards Angell Palmer & Dodge LLP</u>
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		<u>Small Entity</u>		<u>Small Entity</u>		<u>Small Entity</u>	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Fee (\$)	Small Entity Fee (\$)
Fee Description							
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims			
_____ - = _____ x _____ = _____				Fee (\$)		Fee Paid (\$)	
HP = highest number of total claims paid for, if greater than 20.							
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)				
_____ - = _____ x _____ = _____							
HP = highest number of independent claims paid for, if greater than 3.							
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
_____ - 100 = _____ /50 _____ (round up to a whole number) x _____ = _____							
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)						Fees Paid (\$)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	50,649
Name (Print/Type)	Matthew M. Beaudet	Telephone	(617) 239-0614
		Date	April 24, 2007

Application No.: 10/809,689

1

Docket No.: 2004(217246)



Docket No.: 2004(217246)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark Larche et al.

Application No.: 10/809,689

Confirmation No.: 7876

Filed: March 25, 2004

Art Unit: 1644

For: Methods and Compositions for
Desensitization

Examiner: N. M. Rooney

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

04/27/2007 SLUANG1 00000029 041105 10809689

01 FC:1806 180.00 DA

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is given.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 2004(217246). A duplicate copy of this paper is enclosed.

Dated: April 24, 2007

Respectfully submitted,

By

Matthew M. Beaudet

Registration No.: 50,649

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 239-0614

Attorneys/Agents For Applicant



Application No. (if known): 10/809,689

Attorney Docket No.: 2004(217246)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV971738791US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 24, 2007
Date


Signature

Alyson J. Lucas

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Fee Transmittal (1 page)
IDS (Citation) by Applicant (21 References) (2 pages)
Information Disclosure Statement (2 pages)
Transmittal (1 page)
Charge \$180.00 to deposit account 04-1105
Return Post Card



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/809,689
				Filing Date	March 25, 2004
				First Named Inventor	Mark Larche
				Art Unit	1644
				Examiner Name	N. M. Rooney
Sheet	1	of	2	Attorney Docket Number	2004(217246)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,547,669			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-91/06571	05-16-1991	Gefter, et al.		
	BB	WO-92/11859	07-23-1992	Lamb, et al.		
	BC	WO-93/08280	04-29-1993	Rogers, et al.		
	BD	WO-93/19178	09-30-1993	Gefter, et al.		
	BE	WO-94/24281	10-27-1994	Garman, et al.		
	BF	WO-94/27634	12-08-1994	Thomas, W.R.		
	BG	WO-95/26980	10-12-1995	Hackett, et al.		
	BH	WO-96/07428	03-14-1996	Gefter, et al.		
	BI	WO-97/35193	09-25-1997	Kay, et al.		
	BJ	EP-0923940	06-23-1999	Sone, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Akdis, et al., "Epitope-specific T Cell Tolerance to Phospholipase A2 in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 In Vitro" (1996) <i>J.Clin.Invest.</i> 98 :1676-1683.		
	CB	Barnes, et al., "Therapeutic Strategies for Allergic Diseases" (1999) <i>Nature</i> 402 : B31-B38.		
	CC	Bauer, et al., "Modulation of the Allergic Immune Response in BALB/c Mice by Subcutaneous Injection of High Doses of the Dominant T Cell Epitope from the Major Birch Pollen Allergen Bet v 1" (1997) <i>Clin.Exp.Immunol.</i> 107 :536-541.		
	CD	Cao, et al., "Vaccination with a Multi-epitopic Recombinant Allergen Induces Specific Immune Deviation via T-cell Anergy" (1997) <i>Immunology</i> 90 :46-51.		
	CE	Evavold, B.D. and Allen, P.M., "Separation of IL-4 Production from Th Cell Proliferation by an Altered T Cell Receptor Ligand" (1991) <i>Science</i> 252 :1308-1310.		
	CF	Higgins, et al., "Overlapping T-cell Epitopes in the Group I Allergen of <i>Dermatophagoides</i> Species Restricted by HLA-DP and HLA-DR Class II Molecules" (1994) <i>J.Allergy. Clin. Immunol.</i> 93 :891-899.		
	CG	Hogger and Rohdewald, "Binding Kinetics of Fluticasone Propionate to the Human Glucocorticoid Receptor" (1994) <i>Steroid</i> 59 :597-602.		
	CH	Sloan-Lancaster, et al., "Induction of T-cell Anergy by Altered T-cell-receptor Ligand on Live Antigen-presenting Cells" (1993) <i>Nature</i> 363 :156-159.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/809,689
				Filing Date	March 25, 2004
				First Named Inventor	Mark Larche
				Art Unit	1644
				Examiner Name	N. M. Rooney
Sheet	2	of	2	Attorney Docket Number	2004(217246)

CI	Smilek, et al., "A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to Prevent Rather Than Induce Experimental Autoimmune Encephalomyelitis" (1991) <i>PNAS</i> 88:9633-9637.	
CJ	Wheeler & Drachenberg., "New Routes and Formulations for Allergen-specific Immunotherapy" (1997) <i>Allergy</i> 52:602-612.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--